Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EPCORITAMAB-BYSP for Lymphoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 7 adverse event reports in the FDA FAERS database where EPCORITAMAB-BYSP was used for Lymphoma.

Most Reported Side Effects for EPCORITAMAB-BYSP

Side Effect Reports % Deaths Hosp.
Cytokine release syndrome 369 37.7% 136 87
Diffuse large b-cell lymphoma 206 21.1% 112 25
Diffuse large b-cell lymphoma refractory 198 20.3% 101 25
Pyrexia 79 8.1% 29 26
Immune effector cell-associated neurotoxicity syndrome 77 7.9% 34 28
Covid-19 39 4.0% 18 18
Neutrophil count decreased 35 3.6% 11 12
Hypogammaglobulinaemia 32 3.3% 7 8
Platelet count decreased 32 3.3% 11 11
Cytomegalovirus infection 31 3.2% 10 12
Pneumonia 29 3.0% 16 13
Cytomegalovirus infection reactivation 26 2.7% 7 5
Death 25 2.6% 25 4
Malignant neoplasm progression 24 2.5% 10 1
Hypoalbuminaemia 20 2.0% 8 4

Other Indications for EPCORITAMAB-BYSP

Diffuse large b-cell lymphoma (362) Diffuse large b-cell lymphoma refractory (353) Product used for unknown indication (64) Diffuse large b-cell lymphoma recurrent (26) Follicular lymphoma (19) B-cell lymphoma (16) B-cell lymphoma refractory (15) Follicular lymphoma refractory (12) High-grade b-cell lymphoma (10)

Other Drugs Used for Lymphoma

RITUXIMAB (3,142) CYCLOPHOSPHAMIDE (1,729) VINCRISTINE (1,452) LENALIDOMIDE (1,427) DOXORUBICIN (1,420) ETOPOSIDE (915) IBRUTINIB (896) PREDNISONE (672) METHOTREXATE (647) CYTARABINE (645)

Related Pages

EPCORITAMAB-BYSP Full Profile All Lymphoma Drugs EPCORITAMAB-BYSP Demographics EPCORITAMAB-BYSP Timeline